Emerging Markets Earnings Roundup: Merck, Bristol Myers Squibb, Novo Nordisk (Part 12)
This article was originally published in PharmAsia News
Executive Summary
Merck played cat and mouse on the first quarter earnings call, but its subsequent deal with Bayer put the remarks in context. Bristol Myers Squibb has to wait on China for approval there of its diabetes deal with AstraZeneca and Novo Nordisk gets hit by emerging market currencies.
You may also be interested in...
Merck Not Feeling Mega-Merger Mania Even As Pharma Sales Decline
Patent expiries for five products drag down revenue, but biotech deals and pipeline building remain Merck’s strategy, CEO Frazier says.
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.